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was detected. In the four cases with vein stenosis that accounted for the failure to show significant difference
underwent angioplasty the fistulas still failed to develop in renal function compared to the control group. None-
adequately. One patient had a complete occlusion of the theless, the degree of proteinuria was significantly less
subclavian vein. In two patients the fistulogram did not in the treatment arm. The main finding from this five-
reveal any anatomic abnormality. year assessment, however, was that patients who stopped
Finally, notwithstanding the theoretical concerns treatment had significantly worse renal function and
about developing hand ischemia with an upper arm fis- were more likely (6 of 14) to progress to end-stage renal
tula, only one of the 51 consecutive patients in our study disease (ESRD) compared to those who continued treat-
receiving such a fistula developed a clinically significant ment (0 of 13).
steal syndrome. Thirty-one of the patients receiving an Clearly, this finding may be criticized for selection
upper arm fistula were diabetic. bias, since patients who opted to continue treatment may
Michael Allon be more compliant and other confounding factors will
The University of Alabama at Birmingham, Room 129, 1809 influence any analysis made with the RCT as we had
Fifth Avenue South, Birmingham, Alabama 35233-6959, USA.
originally cautioned. This also applies to the interpreta-
tion made by Nolin and Courteau that the benefit seenREFERENCES
at the end of our RCT was not sustained at five years
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biopsy data in relation to the patients included in ourin hemodialysis patients. Kidney Int 56:275–280, 1999
2. Beathard GA, Settle SM, Shields MW: Salvage of the nonfunc- RCT has in fact been published [5], and did reveal sig-
tioning arteriovenous fistula. Am J Kidney Dis 33:5:910–916, 1999 nificantly less histologic progression among patients in
the treatment group.
We would concur with the authors that cyclophos-Dipyridamole and low-dose
phamide is no longer justified in the management of IgA
nephropathy because of its toxicity. It is because of ourwarfarin without
clinical observations, the findings of the five-year assess-
ment, as well as the experimental evidence of a renopro-cyclophosphamide in
tective role of dypyridamole and warfarin through im-
mune, anti-platelet and anti-thrombotic mechanisms thatthe management of
we proceeded to a RCT using this regimen [6]. This
three-year trial included 21 patients with IgA nephropa-IgA nephropathy
thy and mild renal impairment, 10 patients assigned to
To the Editor: We were most interested to read the treatment with dipyridamole and low-dose warfarin
recent Kidney International article on evidence-based (keeping the thrombotest between 30 and 50%), and 11
recommendations in the management of IgA nephropa- patients to the control group on no treatment. At the
thy by Nolin and Courteau [1]. Recommendation 2 end of the trial, renal function remained stable in patients
(grade A) states that treatment with cyclophosphamide, on treatment while a significant deterioration was seen
dipyridamole, and warfarin should not be used. This is in the control group. This study suggests that treatment
based on the results from two randomized controlled of patients with IgA nephropathy and renal impairment
trials (RCT), our own three-year study [2], and that of with dipyridamole and low-dose warfarin retards the de-
Walker et al [3], as well as our five-year post-trial assess- terioration in renal function.
ment [4], concern about the absence of post-treatment Walker et al showed reduction in proteinuria over a
biopsy data, and the potential toxicity from cyclophos-
two-year period but, unlike our original study using the
phamide.
same triple regimen and the subsequent trial withoutThe authors correctly state that we were able to dem-
cyclophosphamide, failed to show any beneficial effectonstrate reduction in proteinuria and stabilization in re-
on renal function [3]. The reasons for this difference maynal function at the end of the three-year trial. However,
be related to the shorter duration of treatment (2 yearsthe apparent loss of benefit on renal function at the five-
vs. 3 years) and the use of warfarin at the higher “anti-year post-trial assessment has been misinterpreted and
coagulant doses” (keeping thrombotest between 7 andneeds to be qualified. Only half the patients in the treat-
15%).ment group remained on treatment with dipyridamole
Currently there is no therapy that will cure IgA ne-and low-dose warfarin at five years, which may have
phropathy. It is the most common form of glomerulone-
phritis worldwide, and is especially frequent in the East
among the Chinese and Japanese and an important cause
of ESRD. While we agree with Nolin and Courteau that 2000 by the International Society of Nephrology
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cyclophosphamide cannot be recommended, we suggest
Detection of fragments ofthat there is available evidence to support the use of
dipyridamole and low-dose warfarin. This regimen has
b2-microglobulin inbeen shown to be safe and its use as long-term therapy
in patients with IgA nephropathy with poor prognostic
amyloid fibrilsindices can slow the rate of decline in renal function and
progression to ESRD.
To the Editor: A major controversy regarding dialysis
related amyloidosis (DRA) is about the presence and
K.T. Woo, G.S.L. Lee, and Abeed A. Pall the role of truncated forms of b2-microglobulin (b2M)Department of Renal Medicine, Singapore General Hospital,
in the amyloid fibrils. Whereas Linke et al have reportedSingapore
the presence of proteolyzed forms of b2M in the amyloid
Correspondence to Dr. K.T. Woo, Department of Renal Medicine, deposits in over 12 cases [1], other groups have not con-
Singapore General Hospital, Outram Road, Singapore 169608. firmed this finding [2]. A similar analysis conduced in
our laboratory with b2-fibrils obtained from six patients
REFERENCES (Table 1) confirms Linke’s data.
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tients with IgA nephropathy and renal impairment. Nephrology
which the fragments were not detected, the purification3:117–121, 1997
of b2M was accomplished by chromatofocusing in non-
denaturing conditions in which the loss of fragments
Reply from the authors can be expected. We think that the use of a protein
sequenator like the HP G1000, in use in our laboratory,To the Editor: Drs. Woo, Lee, and Pall correctly as-
where it is possible to analyze samples in GdnHCl with-sumed that the study “Three-year randomized controlled
out further handling, could avoid the loss of even pmolestrial of dipyridamole and low-dose warfarin in patients
of misfolded b2M fragments.with IgA nephropathy and renal impairment” (Nephrol-
ogy 3:117–121, 1997) was not included in the literature
Monica Stoppini, Patrizia Arcidiaco, Palma Mangione,we reviewed because it was published after the period
Sofia Giorgetti, Diego Brancaccio, and Vittorio Bellotticovered by our Medline research (1976 through Decem- Department of Biochemistry, University of Pavia, Research Labo-
ber 1996). ratory of Biotechnology, IRCCS Policlinico S. Matteo, and Centro
Grandi Strumenti, University of Pavia, Pavia; and Renal Unit,Their study can be classified as level 1 evidence and
Ospedale S. Paolo, Milano, Italytherefore could support a grade A recommendation for
the treatment of IgA nephropathy (IgAN). However,
we are concerned by the small number of patients in-
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